Expression of Cell Adhesion Molecules, Estrogen Receptor, and Progesterone Receptor and Their Significance in Invasive Ductal Carcinoma and Invasive Lobular Carcinoma of Breast
10.3321/j.issn:1000-467X.2001.03.007
- VernacularTitle:乳腺浸润性导管癌和浸润性小叶癌细胞粘附分子与雌、孕激素受体表达及意义
- Author:
An-Jia HAN
1
;
Min XIONG
;
Zhi LI
Author Information
1. Sun Yat-sen University of Medical Sciences
- From:Chinese Journal of Cancer
2001;20(3):258-261
- CountryChina
- Language:Chinese
-
Abstract:
Objective：This study was designed to investigate the cell adhesion molecule, estrogen receptor (ER), and progesterone receptor (PR) expression and their significance in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC)of breast. Methods：Immunohistochemistry staining (labeled streptavidin-biotin method) was used to detect E-cadherin, α -catenin， β -catenin， γ -catenin, ER and PR expression in breast invasive carcinoma (32 cases of the IDC and 10 cases of the ILC). Results：The expression rates of E-cadherin, α -catenin， β -catenin， γ -catenin showing loss or mostly reduced in IDC were 18.7％ ， 75％ ， 43.8％ , and 81.3％ , respectively. The expression rate of E-cadherin, α -catenin， β -catenin， γ -catenin expression showing loss and mostly reduced in ILC were 30％ ， 70％ , 50％ , and 80％ , respectively. There was a positive relationship between the expression of α -catenin and β -catenin in IDC. γ -catenin expression showing loss and mostly reduced in breast invasive carcinoma was associated with the presence of lymph node metastasis. ER expression correlated with PR expression in IDC. Conclusion：In contrast to E-cadherin expression, α -catenin， β -catenin， γ -catenin expression may be almost identical in ILC and IDC, which is showing loss and mostly reduced protein expression in carcinoma cells of breast invasive carcinoma. γ -catenin expression showing loss and mostly reduced is a predictor for the presence of lymph node metastasis. ER, PR and E-cadherin, α -catenin， β -catenin， γ -catenin expression may be two kinds of independent prognostic markers for breast invasive carcinoma.
